← board
AARD
Aardvark Therapeutics, Inc.distress 5/10 · elevated risk$6.50+0%today-63% from 52w high
Lead: obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$91M
Runway
1.5 yrs
Shares 1y
+1%
Price & events
-56.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
+2.7%
1W
+53.7%
1M
+21.0%
3M
-56.7%
6M
-54.3%
1Y
—
2Y
—
5Y
-54.6%
All
Overview
- Market Cap
- $141.81M
- Volume
- 13.41K
- 52 Week Range
- $3.48 – $17.41
- Total Shares
- 21.82M
- Float Shares
- 10.91M
- Short %
- 3.67%
- % Held by Insiders
- 16.12%
- % Held by Institutions
- 56.23%
- RVOL
- 0.04x
Pipeline stages · 1 programs
Low Dose ARD-501, High Dose ARD-501
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-01-13 | Phase 2 | Low Dose ARD-501, High Dose ARD-501 | Autism Spectrum Disorder | 5 | completed |
Catalyst news & presentations · 7
- third quarter of 2026Guided 70%readoutPhase 3ARD-101 · Topline data readout for Phase 3 HERO trialSEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- 1H 2026trial initiationsecondaryPhase 2ARD-201 · Phase 2 STRENGTH trial to evaluate ARD-201 for weight loss alone and with GLP-1RA therapy.SEC 8-K
- 2026-05-14clinical holdARD-101 · FDA placed a full clinical hold on the IND for ARD-101.SEC 8-K
- 2026-02-27safety signalARD-101 · Voluntary pause of Phase 3 HERO trial due to reversible cardiac observations at above-therapeutic doses in healthy volunteers.SEC 8-K
- 2H 2025trial initiationsecondaryPhase 2ARD-201 · Initiate POWER trial for weight maintenanceSEC 8-K
- 2025-10-08fda agreementARD-101 · FDA alignment on protocol amendment to expand Phase 3 HERO trial minimum age from 13 to 10 years old.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $15 (+123% upside) · 10 analysts
- 2026-07-20HC Wainwright & Co.Neutral
- 2026-05-15Morgan StanleyEqual-Weight → Underweight
- 2026-05-15B. Riley SecuritiesBuy
- 2026-05-15BTIGBuy → Neutral
- 2026-03-24BTIGBuy
- 2026-03-02Morgan StanleyOverweight → Equal-Weight
Competitors — obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-23Wix.com (WIX) 27% Drop Prompts Investor Scrutiny – HBSS Investigating Unanticipated Spike in Operating Expenses - GlobeNewswire
- 2026-07-23The Ensign Group (ENSG) Shares Fall Amid Activist Forensic - GlobeNewswire
- 2026-07-20AARD Reiterates by HC Wainwright & Co. -- Price Target Announced at $6.00 - GuruFocus
- 2026-07-20AARD Reiterates by HC Wainwright & Co. -- Price Target Announced at $6.00 - GuruFocus
- 2026-07-20Ram Selvaraju Maintains Hold on Aardvark, Assigns $6 Valuation Amid FDA Clinical Hold on ARD-101 and Lowered Approval Odds - TipRanks
- 2026-07-13Morgan Stanley downgrades Aardvark Therapeutics (AARD) - MSN
- 2026-07-12Aardvark Therapeutics Company Profile & Introduction - Moomoo
- 2026-07-11Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.